1. Canada Stocks

  2. •

    Consumer non-durables

  3. •

    Food: major diversified
Ramm Pharma Corp

Ramm Pharma Corp

CCSE:RAMM
0.01
CAD
+0.00
(-50.00%)
-0.07EPS
1.79MMarket Cap
Ramm Pharma Corp
CSE:RAMM
(Canadian Securities Exchange)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CAD
0.08
0.06
0.05
0.04
0.03
0.04
0.04
0.03
0.02
Revenue per Share
-0.01
-0.07
-0.07
-0.07
-0.17
-0.06
-0.14
-0.07
-0.07
Basic EPS, GAAP
0.02
-0.02
-0.05
-0.04
-0.05
-0.04
-0.03
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.38
0.36
0.46
0.29
0.25
0.11
0.05
0.04
Book Value per Share
- -
0.38
0.34
0.34
0.28
0.24
0.11
0.05
0.04
Tangible Book Value per Share
101
101
101
108
123
121
119
119
119
Basic Weighted Avg Shares
8
6
5
4
4
5
4
3
2
Sales/Revenue/Turnover
3.99
-34.25
-139.14
-161.37
-203.39
-139.54
-155.35
-127.71
-207.78
Operating Margin (%)
- -
- -
- -
1
1
1
1
1
1
Depreciation Expense
-1
-7
-7
-7
-21
-8
-17
-9
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-8.2
-121.56
-136.47
-172.66
-537.79
-152.43
-380.06
-265.13
-449.07
Profit Margin (%)
-1
35
30
21
13
8
2
-1
-1
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
38
36
56
36
29
14
6
4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-20.09
-15.41
-45.58
-23.74
-76.58
-92.17
-100.14
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Oct'25
Jan'26
Apr'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
119
119
119
Market Capitalization
2
4
2

Working Capital

CAD

•

in mil. unless spec.
Oct'25
Jan'26
Apr'26
Total Current Assets
3
2
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
4
4
3
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-21.73%
-58.21%
Free Cash Flow
- -
-15.62%
-73.8%
Net Income, GAAP
- -
39.03%
-46.01%
Sales/Revenue/Turnover
- -
-7.33%
-22.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
4
2025
1
1
- -
1
3
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
-0.01
-0.1
-0.14
2025
-0.01
- -
- -
-0.06
-0.07
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nestle India Ltd. (NSE:NESTLEIND)
The Kraft Heinz Company (NASDAQ:KHC)
General Mills, Inc. (NYSE:GIS)
Beyond Meat, Inc. (NASDAQ:BYND)
The Kraft Heinz Company (NYSE:KHC)
Efor Yatirim Sanayi Ticaret A.S. (BIST:EFOR)
Business
RAMM Pharma Corp. (CSE:RAMM), founded in 1987 and headquartered in Toronto, Canada, engages in the pharmaceutical and medical product business focused on cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals, cosmetics, nutraceuticals, and hemp-based products. The company offers registered cannabinoid medicines including Epifractan 2% and 5% full-spectrum cannabidiol oral solutions, Xalex 10% pure CBD isolate drops, all approved by Uruguay's Ministry of Public Health for sublingual use under prescription; veterinary cannabinoid products under the Nettavet brand (2%, 5%, and 10% CBD drops for dogs as analgesics and anticonvulsants); pet nutrition lines under Nettapet (puppy, adult, and senior formulas); and cosmetic and nutraceutical items under the Marishanti brand. It operates GMP-certified facilities in Uruguay for cultivation and formulation, Italy for extraction and processing via subsidiary Canapar Corp., and Poland via HemPoland for hemp production, contract manufacturing, and distribution of CannabiGold-branded and private-label products; wholly-owned subsidiaries include Medic Plast S.A., Yurelan S.A., RAMM Pharma Holdings Corp., Canapar Corp., and Hempoland S.p.a Z.o.o., serving markets in Latin America, Europe, Peru, and Brazil. In November 2025, minority shareholders approved a proposed US$5.0 million investment for a 10% equity stake in The Global South S.A.S. (post-money valuation US$50 million), plus a five-year call option for an additional 15% at a US$400 million valuation, subject to financing, definitive agreements, and regulatory approvals; the company also maintains a pipeline of hemp-based nutrition and specialized veterinary products.